Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Income (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Net Income for 2 consecutive years, with $77.9 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 533.3% to $77.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 102.35% year-over-year, with the annual reading at $1.1 million for FY2025, 102.35% up from the prior year.
  • Net Income hit $77.9 million in Q4 2025 for Silence Therapeutics, up from -$21.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $77.9 million in Q4 2025 to a low of -$35.5 million in Q3 2024.